Bicoll

Executive Summary

Bicoll GmbH is a German biotechnology company established in 2003 that specializes in discovering and developing novel small molecules derived from natural compounds. The company combines medicinal chemistry expertise with AI/machine learning to create proprietary plant-based libraries for pharmaceutical, nutraceutical, and cosmetic applications. Its current focus is on developing preclinical candidates for neurodegenerative disorders and longevity, addressing significant unmet medical needs in aging populations. Bicoll's platform enables efficient identification and optimization of natural product leads, positioning it in the growing intersection of AI-driven drug discovery and natural product chemistry. As a private, pre-clinical company, Bicoll's near-term outlook depends on advancing its pipeline toward IND-enabling studies and securing partnerships or funding to support further development. The company's long-standing presence in the field (since 2003) and its differentiated natural compound library provide a foundation for potential value creation. However, the preclinical stage carries inherent risks, and progress will rely on successful validation of its candidates in efficacy and safety studies. Key upcoming milestones include the completion of lead optimization for its primary neurodegenerative program and potential strategic collaborations to leverage its library technology.

Upcoming Catalysts (preview)

• Q4 2026Completion of lead optimization for lead neurodegenerative candidate65% success
• H1 2027Announcement of a research collaboration with a pharmaceutical company40% success
• Q2 2027Series A funding round to support IND-enabling studies50% success